BERKELEY, CA--(Marketwired - Dec 19, 2013) - Dynavax Technologies Corporation (
Dynavax expects to receive the EMA Day 180 List of Outstanding Issues during the first quarter of 2014.
HEPLISAV is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response. Dynavax has worldwide commercial rights to HEPLISAV.
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.
- Pharmaceuticals & Drug Trials
- hepatitis B vaccine
Vice President and Chief Business Officer